High-Risk BCG Naïve Treatment of Choice with Dr. Michael A. O'Donnell, MD

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Michael A. O'Donnell, MD, discusses BCG's role as the standard treatment for non-muscle invasive bladder cancer (NMIBC), emphasizing its global acceptance and long-term efficacy.

In this 20-minute presentation, Dr. O’Donnell stresses that a persistent BCG shortage has necessitated the exploration of alternative therapies, including gemcitabine-docetaxel (Gem/Doce), which has become a de facto standard in the shortage era. Retrospective data comparing Gem/Doce to BCG demonstrate comparable recurrence-free and progression-free survival, with lower toxicity and improved patient quality of life. A biomarker analysis suggests that BCG and Gem/Doce may target different patient populations, potentially affecting personalized treatment selection.

The forum's experts enter the discussion, addressing the potential of immune checkpoint inhibitors in NMIBC, with concerns regarding toxicity, cost, and incremental efficacy over existing treatments. The evolving landscape underscores the need for biomarkers to stratify patients effectively and guide treatment selection.

Don't forget to join the GRU Community: https://grandroundsinurology.com/register/
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!
Category
Oncology
Be the first to comment

Up Next